Original Article

Hydrocortisone with fludrocortisone for septic shock: a systematic review and meta-analysis

Ryo Yamamoto,1 Isao Nahara,2 Mitsunobu Toyosaki,1 Tatsuma Fukuda,3 Yoshiki Masuda,4 and Seitaro Fujishima5

1Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, 2Department of Anesthesiology and Critical Care Medicine, Nagoya Daini Red Cross Hospital, Nagoya, 3Department of Emergency and Critical Care Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, 4Department of Intensive Care Medicine, Sapporo Medical University School of Medicine, Sapporo, and 5Center for General Medicine Education, Keio University School of Medicine, Tokyo, Japan

Aim: Combined hydrocortisone and fludrocortisone therapy for septic shock has not been evaluated with an independent systematic review. We aimed to elucidate the beneficial effects of a dual corticosteroid treatment regime involving both hydrocortisone and fludrocortisone for adult patients with septic shock on mortality.

Methods: We searched the Medline, Cochrane CENTRAL, and ICHUSHI databases for reports published before April 2019. We included randomized controlled trials that compared the use of both hydrocortisone and fludrocortisone with either corticosteroid-free or hydrocortisone-only treatments on adult patients with septic shock. Three researchers independently reviewed the studies. The meta-analyses were undertaken to assess primary outcome (28-day mortality) and secondary outcomes (in-hospital mortality, long-term mortality, shock reversal, and adverse events).

Results: Among the four studies eligible for data synthesis, we included 2,050 patients from three studies for quantitative synthesis. All studies used similar regimens (hydrocortisone and fludrocortisone for 7 days without tapering). The 28-day mortality rate was reduced after dual corticosteroid treatment (risk ratio, 0.88; 95% confidence intervals [CI], 0.78–0.99). The heterogeneity between the studies was low ($I^2 = 0\%$). Patients who underwent dual corticosteroid treatment had lower long-term mortality rates (risk ratio, 0.90; 95% CI, 0.83–0.98) and higher rate of shock reversal after 28 days (odds ratio, 1.06; 95% CI, 1.01–1.12) than control patients. Adverse events (except for hyperglycemia) were similar among the treatment groups.

Conclusions: The available evidence suggests that a combination of fludrocortisone and hydrocortisone is more effective than adjunctive therapy and could be recommended for septic shock.

Key words: fludrocortisone, hydrocortisone, mortality, septic shock, shock reversal

INTRODUCTION

THE BENEFICIAL effects of systematic corticosteroid treatment in adult patients with septic shock have been controversial.1-4 Experimental studies have suggested the pathophysiological changes in the hypothalamic–pituitary–adrenal axis in patients with sepsis,5 giving rise to studies focusing on the therapeutic role of corticosteroids for sepsis and septic shock.6-12 Although corticosteroids have been shown to improve blood pressure,9 there are conflicting results on survival benefits in recent large randomized controlled trials (RCTs) and systematic reviews,1-4,6-8,10-12 resulting in the lack of definitive recommendations in several clinical guidelines.13-15

Some reasons for these contradictory findings include differences in patient populations and the variation in corticosteroid treatments. Low risk-of-bias (RoB) RCTs recruited only patients with septic shock and investigated mortalities as their primary outcomes; however, their definition of refractory shock differed in the doses of vasopressors required.6,8,11,12 The durations, amounts, and type of corticosteroids also differed; due to these inconsistencies, optimal corticosteroid treatments remain unclear.11,12 Moreover, most systematic reviews examined particular corticosteroid therapies only through subgroup analyses.1,2,4

Corresponding: Seitaro Fujishima, MD, PhD, Center for General Medicine Education, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan. E-mail: fujishim@keio.jp

Received 10 Jul, 2020; accepted 2 Aug, 2020

Funding Information
No funding information provided.

© 2020 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Among the various corticosteroid treatments, dual treatment with hydrocortisone and fludrocortisone for septic shock has shown promising results.12 Hydrocortisone has both glucocorticoid and mineralocorticoid activities; whereas fludrocortisone, a synthetic corticosteroid, possesses very potent mineralocorticoid activity.16,17 Hydrocortisone has been extensively examined in sepsis, and fludrocortisone has been used for patients with aldosterone deficiency. Dual therapy using these two medications is recommended for some patients with primary adrenal insufficiency.18 Considering that patients with septic shock have been found to have unexpectedly low aldosterone levels due to hypothalamic–pituitary–adrenal axis abnormalities,19 dual treatment with hydrocortisone and fludrocortisone should be further validated as a type of corticosteroid treatment for septic shock.

Accordingly, we undertook a systematic review and meta-analysis to identify beneficial effects of the dual treatment with hydrocortisone and fludrocortisone for patients with septic shock, when compared to treatment with placebo or hydrocortisone alone. We particularly examined mortality, vasopressor withdrawal, and adverse events (AEs).

**METHODS**

We report our findings in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses Guidelines. The review protocol has been registered with PROSPERO (reference CRD42019139069).

**Search strategy**

Three databases were searched in April 2019: Medline, Cochrane CENTRAL, and ICHUSHI. The search strategy is described in Tables S1, S2, and S3. We also evaluated the reference list of the relevant studies to identify additional sources.1,2,4

**Study selection**

We included RCTs that fulfilled the following criteria: (i) full-text publication in peer-reviewed journals in English or Japanese, (ii) inclusion of adult patients diagnosed with septic shock, according to accepted criteria, (iii) studies comparing the use of both hydrocortisone and fludrocortisone with a corticosteroid-free or hydrocortisone-only comparator group.

Reviewers undertook screenings in duplicate in two stages. First, two independent reviewers (IN and MT) assessed titles and abstracts to identify potentially relevant articles. Then, the reviewers obtained full texts of articles for further review and independently assessed them. Disagreements between the two reviewers were resolved by discussion between them and a third reviewer (RY) until consensus was achieved.

**Data extraction and quality assessment**

The three reviewers extracted the data independently and in duplicate using predefined data abstraction forms. The RoB was then evaluated for each outcome of individual studies using the Cochrane risk of bias assessment tool.

**Data synthesis and analysis**

The primary outcome was 28-day mortality. The secondary outcomes included in-hospital mortality, long-term mortality (longer than 90 days), shock reversal at day 28 defined as vasopressor withdrawal at day 28, vasopressor-free days up to day 28, and the prevalence of AEs such as superinfection, gastrointestinal (GI) bleeding, hyperglycemia, hypernatremia, and any other events related to corticosteroid treatment. Subgroup analyses were prespecified according to duration of treatment and dose of hydrocortisone and/or fludrocortisone. Sensitivity analyses were carried out by repeating meta-analyses, in which we defined control groups as either patients not treated with corticosteroid (placebo) or patients treated only with hydrocortisone (hydrocortisone-only).

We used the Review Manager software (RevMan version 5.3; The Cochrane Collaboration, Copenhagen, Denmark) to undertake the meta-analyses. We used a random-effects model to calculate pooled effect sizes and 95% confidence intervals (CIs) for outcomes except for shock reversal at day 28, in which a fixed-effects model was used because the effect was estimated to be in the same direction based on previous studies.1,4 We presented results as risk ratios (RRs) for dichotomous outcomes and as mean differences for continuous outcomes. Heterogeneity between studies was assessed using the $\chi^2$-test for homogeneity, $I^2$ statistic, and visual inspection of forest plots. Publication bias was also evaluated by a funnel plot. The overall certainty of evidence was rated using the Grading of Recommendations Assessment, Development, and Evaluation approach.

**RESULTS**

**Study selection**

We identified 94 articles through the Medline search, 35 through the Cochrane CENTRAL search, and two articles through the ICHUSHI search. Eleven studies were considered potentially eligible; we then excluded...
seven after the full-text screening. Among four studies eligible for data synthesis, we included a total of 2,050 patients from three studies for our quantitative synthesis (one study did not report any targeted outcome; Fig. 1).

**Description of eligible studies**

Table S4 presents a description of the eligible studies. All studies were undertaken at multiple centers, and their eligibility criteria included the requirement of vasopressors to define septic shock. All studies also used the same intervention protocol in terms of type, dose, and duration of the corticosteroid therapy; hydrocortisone was given as a 50 mg i.v. bolus every 6 h, and fludrocortisone as a 50 μg tablet once daily for 7 days (without tapering). Three of the eligible studies used placebo for the control group, and the other used the hydrocortisone alone therapy (a 50 mg i.v. bolus every 6 h) for the control group. One of the eligible studies reported only hematological and biochemical outcomes obtained from the same population of another included study; therefore, we did not include it in the quantitative synthesis.

**Primary outcome**

Two studies reported 28-day mortalities, and our analyses showed the 28-day mortality rate was lower in the dual corticosteroid treatment patients than in the controls, and the RR of 28-day mortality was 0.88 (95% CI, 0.78–0.99) with low heterogeneity ($I^2 = 0\%$, $P = 0.79$; Fig. 2). Publication bias was not estimated using the funnel plot because only two studies were included in the meta-analysis. Prespecified subgroup analysis was not undertaken regarding the primary outcome because the duration and dose of the corticosteroid treatments were identical between the two studies. Sensitivity analysis was not applied on the primary outcome because

---

**Fig. 1. Study selection flow diagram.** Among four studies eligible for data synthesis, a total of 2,050 patients from three studies were included for quantitative synthesis.
the control groups of both studies were cortisol-free (placebo) populations.

Secondary outcomes

In-hospital mortalities and long-term mortalities were reported in three studies.\textsuperscript{6,12,20} In-hospital and long-term mortalities were lower in the patients treated with both hydrocortisone and fludrocortisone (RR = 0.89; 95% CI, 0.81–0.97; and RR = 0.90; 95% CI, 0.83–0.98, respectively) with low heterogeneity (Fig. S1).

Shock reversal at day 28 was reported in two included studies, whereas vasopressor-free days of up to day 28 were reported in only one included study. Patients in the dual corticosteroid treatment group had a higher rate of shock reversal (RR = 1.06; 95% CI, 1.01–1.12)\textsuperscript{6,12} and more vasopressor-free days (mean difference = 2.0 days; 95% CI, 0.8–3.2 days)\textsuperscript{12} than patients in the control group (Fig. 3).

Meta-analyses on AEs by corticosteroid treatment revealed that risks of superinfection,\textsuperscript{6,12,20} GI bleeding,\textsuperscript{6,12} and psychiatric disorder\textsuperscript{6} were similar between the dual corticosteroid treatment and the control groups (Fig. S2)). The incidence of hyperglycemia was higher in patients treated with both hydrocortisone and fludrocortisone, although only one study reported hyperglycemia as an AE (Fig. S2).\textsuperscript{12}

We did not undertake prespecified subgroup analyses on secondary outcomes because the duration and dose of corticosteroid treatments were identical among all included studies. Sensitivity analyses were carried out on in-hospital mortality, long-term mortality, and superinfection because the control groups comprised both a corticosteroid-free population and a hydrocortisone-only population. Meta-analyses comparing the dual corticosteroid treatment with placebo showed that in-hospital and long-term mortalities were lower in the dual corticosteroid group than in the placebo group (RR = 0.88; 95% CI, 0.80–0.98; and RR = 0.89; 95% CI, 0.81–0.97, respectively), whereas AEs were comparable between the groups (Fig. S3).\textsuperscript{6,12} A sensitivity analysis comparing the dual corticosteroid treatment with hydrocortisone-only therapy revealed a higher superinfection rate in the dual corticosteroid treatment group (RR = 1.54; 95% CI, 1.05–2.26), whereas in-hospital and long-term mortalities were comparable between the groups (Fig. S4).\textsuperscript{20} Table 1 summarizes results according to control groups.

Risk of bias and summary of findings

The RoB for mortality was evaluated as “low” for all components of the Cochrane risk of bias assessment, with the
exception of the “unclear risk” at “selective outcome reporting” in the study by Annane et al. in 2002 (Fig. S5).

The quality of evidence for each outcome is summarized in Table 2. The 28-day and long-term mortalities were significantly reduced by the dual therapy with both hydrocortisone and fludrocortisone with high certainty. Among the AEs associated with corticosteroid treatment, the incidence of hyperglycemia was increased by the dual corticosteroid treatment with high certainty.

DISCUSSION

W E UNDERTOOK THE systematic review and meta-analysis to evaluate the effects of dual corticosteroid treatment in terms of clinical outcomes in patients with septic shock. Although previous systematic reviews had shown conflicting results, we found a reduced mortality with high certainty: 28-day, in-hospital, and long-term (later than 90 days) mortalities were reduced by treatment with both hydrocortisone and fludrocortisone.

The main difference between the current study and other meta-analyses is the fact that we examined only the effects of the dual corticosteroid treatment for septic shock. The idea behind the addition of fludrocortisone to hydrocortisone, used as glucocorticoid replacement therapy in patients with adrenal insufficiency, is to enhance the mineralocorticoid activity. Mineralocorticoids are known to affect salt and water balance, whereas glucocorticoids preferentially affect sugar metabolism and exhibit sex hormone activities, suggesting that mineralocorticoids would play a role in fluid retention among patients with septic shock. The biological activity of mineralocorticoids is mediated by the mineralocorticoid receptor (MR), which exists in various organs, such as the kidneys, cardiovascular, immune, and central nervous systems. Potential immune effects of mineralocorticoids through non-renal MR have been suggested, and animal studies found an association between sepsis and the downregulation of the MR in endothelial cells. Mineralocorticoid supplementation lowered IL-6 levels, hastened shock reversal, and improved survival. Some clinical studies also revealed inappropriately low aldosterone levels in patients with septic shock, suggesting an impaired adrenal synthesis of aldosterone, which might be associated with increased mortality.

The meta-analyses on the secondary outcomes found that the incidence of AEs was not increased by the dual corticosteroid treatment, except for hyperglycemia, which is consistent with a systematic review examining all types of corticosteroid therapies for sepsis. In that study, the risks for hyperglycemia, hypernatremia, and neuromuscular weakness were similarly increased by corticosteroid treatment, whereas the incidence of superinfections, GI bleeding, and psychiatric disorders remained similar to those in control patients. Considering that MRs are expressed in monocytes and macrophages that undergo a pro-inflammatory polarization in response to mineralocorticoids,
pathophysiological immunomodulatory changes by the additional mineralocorticoid treatment should be further examined.

Fludrocortisone use was optional in a previous version of the Surviving Sepsis Campaign guidelines, and it was removed from the most recent guidelines in 2016. Two recent systematic reviews evaluated heterogeneity in types of corticosteroid treatments, and did not find a credible effect of the specific type of corticosteroid treatment. However, these analyses did not examine the direct

Table 1. Results of a systematic review of hydrocortisone and fludrocortisone for septic shock, according to control group

| Outcome                      | Risk ratio (95% confidential interval) | Overall | Versus corticosteroid-free | Versus hydrocortisone only |
|------------------------------|----------------------------------------|---------|---------------------------|---------------------------|
| Mortality                    |                                        |         |                           |                           |
| 28-day mortality             | 0.88 (0.78–0.99)                      | 0.88 (0.78–0.99) | N/A                       |
| In-hospital mortality        | 0.89 (0.81–0.97)                      | 0.88 (0.80–0.98) | 0.91 (0.75–1.11)          |
| Long-term mortality          | 0.90 (0.83–0.98)                      | 0.89 (0.81–0.97) | 0.94 (0.78–1.13)          |
| Shock reversal               |                                        |         |                           |                           |
| Vasopressor withdrawal at day 28 | 1.06 (1.01–1.12) | 1.06 (1.01–1.12) | N/A                       |
| Vasopressor-free days up to day 28 (days) | 2.0 (0.8–3.2) | 2.0 (0.8–3.2) | N/A                       |
| Adverse events               |                                        |         |                           |                           |
| Superinfection               | 1.14 (0.85–1.51)                      | 1.08 (0.86–1.35) | 1.54 (1.05–2.26)          |
| GI bleeding                  | 0.96 (0.66–1.39)                      | 0.96 (0.66–1.39) | N/A                       |
| Hyperglycemia                | 1.07 (1.03–1.12)                      | 1.07 (1.03–1.12) | N/A                       |
| Psychiatric disorders        | 0.33 (0.01–8.06)                      | 0.33 (0.01–8.06) | N/A                       |

Bold values indicate significant difference.

GI, gastrointestinal; N/A, not applicable.

Table 2. Summary of findings of a systematic review of hydrocortisone and fludrocortisone for septic shock

| Outcomes                  | No. of studies | No. of patients | Effect estimates | Certainty in effect estimates† | Certainty assessment |
|---------------------------|----------------|-----------------|------------------|-------------------------------|----------------------|
|                           |                | HC + FC         | Control          | Relative effect (95% CI)      | Absolute effect (95% CI) |                       |
| 28-day mortality          | 2              | 289/764 (37.8%) | 335/776 (43.2%)  | RR 0.88 (0.78 to 0.99)        | 52 fewer per 1,000 (4 fewer to 95 fewer) | High                  |
|                           |                |                 |                  |                               | 0.99 (0.88 to 1.09)     |                       |
| Long-term mortality (90 days to 1 year) | 3              | 478/1,009 (47.4%) | 548/1,040 (52.7%) | RR 0.90 (0.83 to 0.98)        | 53 fewer per 1,000 (11 fewer to 96 fewer) | High                  |
|                           |                |                 |                  |                               | 0.99 (0.87 to 1.03)     |                       |
| Shock reversal (at day 28) | 1              | 603/761 (79.2%) | 569/775 (73.4%)  | RR 1.06 (1.01 to 1.12)        | 44 more per 1,000 (7 more to 88 more) | Moderate              |
|                           |                |                 |                  |                               | 0.99 (0.95 to 1.04)     |                       |
| Superinfection            | 3              | 266/1,009 (26.4%) | 242/1,039 (23.3%) | RR 1.14 (0.85 to 1.51)        | 33 more per 1,000 (35 fewer to 119 more) | Low                   |
|                           |                |                 |                  |                               | 0.99 (0.91 to 1.07)     |                       |
| GI bleeding               | 2              | 50/764 (6.5%)   | 53/775 (6.8%)    | RR 0.96 (0.66 to 1.39)        | 3 fewer per 1,000 (23 fewer to 27 more) | Low                   |
|                           |                |                 |                  |                               | 0.99 (0.81 to 1.30)     |                       |
| Hyperglycemia             | 3              | 547/614 (89.1%) | 520/626 (83.1%)  | RR 1.07 (1.03 to 1.12)        | 58 more per 1,000 (25 more to 100 more) | High                  |
|                           |                |                 |                  |                               | 0.99 (0.95 to 1.12)     |                       |
| Psychiatric disorders     | 3              | 0/150 (0.0%)    | 1/149 (0.7%)     | RR 0.33 (0.01 to 8.06)        | 4 fewer per 1,000 (6 fewer to 47 more) | Low                   |

CI, confidential interval; FC, fludrocortisone; GI, gastrointestinal; HC, hydrocortisone; RR, risk ratio.

†Certainty in effect estimates was assessed with five domains: study limitations, inconsistency, indirectness, imprecision, and publication bias.

© 2020 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine
association between the dual corticosteroid treatment and clinical outcomes, and based on our results additional use of fludrocortisone would be considered more than just an adjunctive therapy.

There are several limitations in this study. We found only four eligible studies and included only two in the meta-analysis for the primary outcome.6,12 In part because the additional fludrocortisone has not been extensively examined and because we considered only RCTs. However, our search strategy used a wide variety of search terms and the eligibility criteria were wide enough to capture an article by Laviolette et al.21 that was not included in the recent systematic reviews.1,4

Another limitation of this study is the fact that the control group in the meta-analyses consisted of both corticosteroid-free and hydrocortisone-only populations, which could hamper the interpretation of our results. Although some secondary outcomes differed according to the definitions of the comparator group, the reduced 28-day mortality by the dual corticosteroid therapy resulted only from the comparison with placebo.

Moreover, all eligible studies used the same treatment regimen. Although different doses might affect the results, the doses used were consistent with those used in replacement therapy for primary adrenal insufficiency.18,29 Given that a study on different hydrocortisone-only treatment durations for septic shock revealed no differences in outcomes between 3-day and 7-day regimens,30 a shorter regimen of the dual corticosteroid treatment should be investigated.

Finally, one of the included studies reporting 28-day mortality was carried out approximately 20 years ago. As the quality of care for sepsis has significantly improved and the definition of sepsis has changed in the last two decades, the efficacy of dual corticosteroid treatment should be further assessed among patients diagnosed using the current criteria.

CONCLUSIONS

This systematic review clarified that hydrocortisone and fludrocortisone treatment reduces the 28-day mortality of patients with septic shock with minimum risk of AEs. The pathophysiological mechanisms of the additional fludrocortisone and the duration of treatment should be further studied.

DISCLOSURE

Approval of the research protocol: N/A.
Informed consent: N/A.
Registration no.: PROSPERO No. CRD42019139069.

REFERENCES

1. Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Crit. Care Med. 2018; 46: 1411–20.
2. Fang F, Zhang Y, Tang J, et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: A systematic review and meta-analysis. JAMA Intern. Med. 2019; 179: 213–23.
3. Ni YN, Liu YM, Wang YW, Liang BM, Liang ZA. Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta-analysis. Am. J. Emerg. Med. 2019; 37: 1657–64.
4. Rygård SL, Butler E, Granholm A, et al. Low-dose corticosteroids for adult patients with septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018; 44: 1003–16.
5. Mesotten D, Vanhorebeek I, Van den Bergh G. The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat. Clin. Pract. Endocrinol. Metab. 2008; 4: 496–505.
6. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862–71.
7. Tandan S, Guleria R, Gupta N. Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India. Am. J. Respir. Crit. Care Med. 2005; 171: 43A.
8. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med. 2008; 358: 111–24.
9. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131: 954–63.
10. Keh D, Trips E, Marx G, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 2016; 316: 1775–85.
11. Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N. Engl. J. Med. 2018; 378: 797–808.
12. Annane D, Renauld A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N. Engl. J. Med. 2018; 378: 809–18.

© 2020 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017; 45: 486–552.

Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017; 43: 1751–63.

Nishida O, Ogura H, Egi M, et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2016 (J-SSCG 2016). Acute Med. Surg. 2018; 6: 7.

Heming N, Sivanandumooorthy S, Meng P, Bounab R, Annane D. Immune effects of corticosteroids in sepsis. Front. Immunol. 2018; 9: 1736.

Hamiouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B. Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers. AAPS J. 2017; 19: 727–35.

Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2016; 101: 364–89.

Moraes RB, Friedman G, Viana MV, Tonietto T, Saltz H, Czepielewski MA. Aldosterone secretion in patients with septic shock: a prospective study. Arq Bras Endocrinol. Metab. 2013; 57: 636–41.

COIITSS Study Investigators, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303: 341–8.

Laviolle B, Annane D, Fougerou C, Bellissant E. Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock. Intensive Care Med. 2012; 38: 1306–14.

Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006; 126: 789–99.

Fadel F, André-Grégoire G, Gravez B, et al. Aldosterone and vascular mineralocorticoid receptors in murine endotoxic and human septic shock. Crit. Care Med. 2017; 45: e954–e962.

Hicks CW, Sweeney DA, Danner RL, et al. Beneficial effects of stress-dose corticosteroid therapy in canines depend on the severity of staphylococcal pneumonia. Intensive Care Med. 2012; 38: 2063–71.

Hicks CW, Sweeney DA, Danner RL, et al. Efficacy of selective mineralocorticoid and glucocorticoid agonists in canine septic shock. Crit Care Med. 2012; 40: 199–207.

du Cheyron D, Lesage A, Daubin C, Ramakers M, Charbonneau P. Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failure. Intensive Care Med. 2003; 29: 1703–9.

Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 2010; 120: 3350–64.

Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 2008; 36: 296–327.

Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287: 236–40.

Huh JW, Choi HS, Lim CM, et al. Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3days with 7 days. Respirology 2011; 16: 1088–95.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

Fig S1. Forest plots of in-hospital and long-term mortalities.

Fig S2. Forest plots of adverse events.

Fig S3. Sensitivity analyses comparing the dual corticosteroid therapy with placebo.

Fig S4. Sensitivity analyses comparing the dual corticosteroid therapy with hydrocortisone-only regimen.

Fig S5. Risk of bias summary.

Table S1. Search strategy overview.

Table S2. Medline search strategy.

Table S3. Cochrane CENTRAL search strategy.

Table S4. Characteristics of the included studies.